Navamedic バランスシートの健全性

財務の健全性基準チェック /46

Navamedicの総株主資本はNOK264.1M 、総負債はNOK121.5Mで、負債比率は46%となります。総資産と総負債はそれぞれNOK527.5MとNOK263.4Mです。 Navamedicの EBIT はNOK42.1Mで、利息カバレッジ比率13.4です。現金および短期投資はNOK46.5Mです。

主要情報

46.0%

負債資本比率

NOK 121.50m

負債

インタレスト・カバレッジ・レシオ	13.4x
現金	NOK 46.47m
エクイティ	NOK 264.13m
負債合計	NOK 263.37m
総資産	NOK 527.50m

財務の健全性に関する最新情報

Recent updates

Is Navamedic (OB:NAVA) Using Too Much Debt?

Sep 19

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Feb 18

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Nov 09

Is Navamedic (OB:NAVA) A Risky Investment?

Nov 02

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Feb 22

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Sep 04

Is Navamedic (OB:NAVA) Using Too Much Debt?

Apr 12

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

Feb 18

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Dec 07

財務状況分析

短期負債: NAVAの短期資産 ( NOK263.9M ) が短期負債 ( NOK161.1M ) を超えています。

長期負債: NAVAの短期資産 ( NOK263.9M ) が長期負債 ( NOK102.3M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: NAVAの純負債対資本比率 ( 28.4% ) は満足できる水準であると考えられます。

負債の削減: NAVAの負債対資本比率は、過去 5 年間で33.3%から46%に増加しました。

債務返済能力: NAVAの負債は営業キャッシュフローによって十分にカバーされていません ( 7.6% )。

インタレストカバレッジ: NAVAの負債に対する利息支払いは EBIT ( 13.4 x coverage) によって十分にカバーされています。

Navamedic バランスシートの健全性

財務の健全性 基準チェック /46

主要情報

財務の健全性に関する最新情報

Is Navamedic (OB:NAVA) Using Too Much Debt?

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Is Navamedic (OB:NAVA) A Risky Investment?

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Is Navamedic (OB:NAVA) Using Too Much Debt?

Recent updates

Consensus EPS estimates fall by 21%

Chief Financial Officer recently bought kr476k worth of stock

Navamedic Launches Eroxon in Finland

New minor risk - Profit margin trend

Third quarter 2024 earnings released

Investor sentiment deteriorates as stock falls 17%

Chief Executive Officer exercised options to buy kr2.2m worth of stock.

Consensus EPS estimates fall by 12%

Director recently bought kr1.5m worth of stock

Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023)

Price target decreased by 7.1% to kr45.50

First quarter 2024 earnings released

An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 28%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings released

Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024

Third quarter 2023 earnings released

Consensus EPS estimates increase by 10%

Is Navamedic (OB:NAVA) Using Too Much Debt?

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 53%

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 16%, revenue upgraded

Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors

First quarter 2023 earnings released

Price target increased by 8.7% to kr50.00

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Full year 2022 earnings released

Consensus EPS estimates increase by 20%, revenue downgraded

Navamedic ASA Launches Modifast in Norway

Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023

Price target increased to kr48.00

No independent directors

Consensus EPS estimates increase by 19%

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Third quarter 2022 earnings released

Is Navamedic (OB:NAVA) A Risky Investment?

Consensus forecasts updated

Price target decreased to kr44.00

Navamedic ASA Launches Forlaxgo®

Consensus EPS estimates increase by 50%

Consensus EPS estimates increase by 30%

Chief Financial Officer exercised options to buy kr2.1m worth of stock.

Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million .

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB.

Price target increased to kr50.00

No independent directors

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Full year 2021 earnings: Revenues exceed analyst expectations

Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea

Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022

Third quarter 2021 earnings released

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020)

Navamedic ASA Announces the Launch of New Products in the Nordics

Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden

First quarter 2021 earnings released

Is Navamedic (OB:NAVA) Using Too Much Debt?

New 90-day high: kr29.00

Full year 2020 earnings released

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

New 90-day high: kr22.60

Is Navamedic (OB:NAVA) Using Debt Sensibly?

財務の健全性基準チェック /46